Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Mapping Quality of Life (EQ-5D) from DAPsA, Clinical DAPsA and HAQ in Psoriatic Arthritis

T. Mlcoch, J. Tuzil, L. Sedova, J. Stolfa, M. Urbanova, D. Suchy, A. Smrzova, J. Jircikova, T. Hrnciarova, K. Pavelka, T. Dolezal,

. 2018 ; 11 (3) : 329-340.

Jazyk angličtina Země Nový Zéland

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc19001081
E-zdroje Online Plný text

NLK ProQuest Central od 2008-01-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest) od 2008-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 2008-01-01 do Před 1 rokem
Family Health Database (ProQuest) od 2008-01-01 do Před 1 rokem
Public Health Database (ProQuest) od 2008-01-01 do Před 1 rokem

BACKGROUND: Clinical trials and observational studies lacking measures of health-related quality of life (QoL) are often inapplicable when conducting cost-effectiveness analyses using quality-adjusted life-years (QALYs). The only solution is to map QoL ex post from additionally collected clinical outcomes and generic QoL instruments. Nonetheless, mapping studies are absent in psoriatic arthritis (PsA). METHODS: In this 2-year, prospective, multicentre, non-interventional study of PsA patients, EQ-5D and key clinical parameters such as Disease Activity in PsA (DAPsA), clinical DAPsA (cDAPsA; DAPsA without C-reactive protein [CRP]), and Health Assessment Questionnaire disability index (HAQ) were collected. We employed a linear mixed-effect regression model (ME) of the longitudinal dataset to explore the best predictors of QoL. RESULTS: A total of 228 patients were followed over 873 appointments/observations. DAPsA, cDAPsA and HAQ were stable and highly significant predictors of EQ-5D utilities in both cross-sectional and longitudinal analyses. The best prediction was provided using a linear ME with HAQ and cDAPsA or DAPsA. A HAQ increase of 1 point represented a decrease in EQ-5D by -0.204 or -0.203 (p < 0.0001); a one-point increase in cDAPsA or DAPsA dropped EQ-5D equally by -0.005 (p < 0.0001). The ME revealed steeper and more accurate association compared with cross-sectional regressions or non-linear models/transformations. CONCLUSIONS: This is the first mapping study conducted in PsA and we hope that our study will encourage further mapping studies in PsA. The results showed that in cases where CRP is absent, cDAPsA provides similar results to DAPsA in predicting QoL.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19001081
003      
CZ-PrNML
005      
20211118143544.0
007      
ta
008      
190107s2018 nz f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s40271-017-0285-1 $2 doi
035    __
$a (PubMed)29164493
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a nz
100    1_
$a Mlcoch, Tomas $u Institute of Health Economics and Technology Assessment, Vaclavska 316/12, 12000, Prague 2, Czech Republic. mlcoch@iheta.org.
245    10
$a Mapping Quality of Life (EQ-5D) from DAPsA, Clinical DAPsA and HAQ in Psoriatic Arthritis / $c T. Mlcoch, J. Tuzil, L. Sedova, J. Stolfa, M. Urbanova, D. Suchy, A. Smrzova, J. Jircikova, T. Hrnciarova, K. Pavelka, T. Dolezal,
520    9_
$a BACKGROUND: Clinical trials and observational studies lacking measures of health-related quality of life (QoL) are often inapplicable when conducting cost-effectiveness analyses using quality-adjusted life-years (QALYs). The only solution is to map QoL ex post from additionally collected clinical outcomes and generic QoL instruments. Nonetheless, mapping studies are absent in psoriatic arthritis (PsA). METHODS: In this 2-year, prospective, multicentre, non-interventional study of PsA patients, EQ-5D and key clinical parameters such as Disease Activity in PsA (DAPsA), clinical DAPsA (cDAPsA; DAPsA without C-reactive protein [CRP]), and Health Assessment Questionnaire disability index (HAQ) were collected. We employed a linear mixed-effect regression model (ME) of the longitudinal dataset to explore the best predictors of QoL. RESULTS: A total of 228 patients were followed over 873 appointments/observations. DAPsA, cDAPsA and HAQ were stable and highly significant predictors of EQ-5D utilities in both cross-sectional and longitudinal analyses. The best prediction was provided using a linear ME with HAQ and cDAPsA or DAPsA. A HAQ increase of 1 point represented a decrease in EQ-5D by -0.204 or -0.203 (p < 0.0001); a one-point increase in cDAPsA or DAPsA dropped EQ-5D equally by -0.005 (p < 0.0001). The ME revealed steeper and more accurate association compared with cross-sectional regressions or non-linear models/transformations. CONCLUSIONS: This is the first mapping study conducted in PsA and we hope that our study will encourage further mapping studies in PsA. The results showed that in cases where CRP is absent, cDAPsA provides similar results to DAPsA in predicting QoL.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a psoriatická artritida $x psychologie $7 D015535
650    _2
$a průřezové studie $7 D003430
650    _2
$a posuzování pracovní neschopnosti $7 D004185
650    _2
$a ženské pohlaví $7 D005260
650    12
$a zdravotní stav $7 D006304
650    _2
$a zdravotnické přehledy $x statistika a číselné údaje $7 D006306
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prospektivní studie $7 D011446
650    _2
$a kvalita života $x psychologie $7 D011788
650    12
$a kvalitativně upravené roky života $7 D019057
650    _2
$a stupeň závažnosti nemoci $7 D012720
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Tuzil, Jan $u Institute of Health Economics and Technology Assessment, Vaclavska 316/12, 12000, Prague 2, Czech Republic.
700    1_
$a Sedova, Liliana $u Institute of Rheumatology, Prague, Czech Republic. Clinic of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Stolfa, Jiri $u Institute of Rheumatology, Prague, Czech Republic. Clinic of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Urbanová, Monika $u Institute of Rheumatology, Prague, Czech Republic. $7 xx0210376
700    1_
$a Suchy, David $u Department of Clinical Pharmacology, Rheumatology, University Hospital Plzen, Plzen, Czech Republic.
700    1_
$a Smrzova, Andrea $u Third Internal Clinic, University Hospital Olomouc, Olomouc, Czech Republic.
700    1_
$a Jircikova, Jitka $u Institute of Health Economics and Technology Assessment, Vaclavska 316/12, 12000, Prague 2, Czech Republic.
700    1_
$a Hrnciarova, Tereza $u Institute of Health Economics and Technology Assessment, Vaclavska 316/12, 12000, Prague 2, Czech Republic.
700    1_
$a Pavelka, Karel $u Institute of Rheumatology, Prague, Czech Republic.
700    1_
$a Dolezal, Tomas $u Institute of Health Economics and Technology Assessment, Vaclavska 316/12, 12000, Prague 2, Czech Republic.
773    0_
$w MED00196809 $t The patient $x 1178-1661 $g Roč. 11, č. 3 (2018), s. 329-340
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29164493 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190107 $b ABA008
991    __
$a 20211118143546 $b ABA008
999    __
$a ok $b bmc $g 1365014 $s 1039204
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 11 $c 3 $d 329-340 $i 1178-1661 $m The patient $n Patient $x MED00196809
LZP    __
$a Pubmed-20190107

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...